Cargando…

Development of ELISA based on Bacillus anthracis capsule biosynthesis protein CapA for naturally acquired antibodies against anthrax

Anthrax is a zoonotic disease caused by the gram-positive spore-forming bacterium Bacillus anthracis. Detecting naturally acquired antibodies against anthrax sublethal exposure in animals is essential for anthrax surveillance and effective control measures. Serological assays based on protective ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Zorigt, Tuvshinzaya, Furuta, Yoshikazu, Simbotwe, Manyando, Ochi, Akihiro, Tsujinouchi, Mai, Shawa, Misheck, Shimizu, Tomoko, Isoda, Norikazu, Enkhtuya, Jargalsaikhan, Higashi, Hideaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504768/
https://www.ncbi.nlm.nih.gov/pubmed/34634075
http://dx.doi.org/10.1371/journal.pone.0258317
_version_ 1784581388234653696
author Zorigt, Tuvshinzaya
Furuta, Yoshikazu
Simbotwe, Manyando
Ochi, Akihiro
Tsujinouchi, Mai
Shawa, Misheck
Shimizu, Tomoko
Isoda, Norikazu
Enkhtuya, Jargalsaikhan
Higashi, Hideaki
author_facet Zorigt, Tuvshinzaya
Furuta, Yoshikazu
Simbotwe, Manyando
Ochi, Akihiro
Tsujinouchi, Mai
Shawa, Misheck
Shimizu, Tomoko
Isoda, Norikazu
Enkhtuya, Jargalsaikhan
Higashi, Hideaki
author_sort Zorigt, Tuvshinzaya
collection PubMed
description Anthrax is a zoonotic disease caused by the gram-positive spore-forming bacterium Bacillus anthracis. Detecting naturally acquired antibodies against anthrax sublethal exposure in animals is essential for anthrax surveillance and effective control measures. Serological assays based on protective antigen (PA) of B. anthracis are mainly used for anthrax surveillance and vaccine evaluation. Although the assay is reliable, it is challenging to distinguish the naturally acquired antibodies from vaccine-induced immunity in animals because PA is cross-reactive to both antibodies. Although additional data on the vaccination history of animals could bypass this problem, such data are not readily accessible in many cases. In this study, we established a new enzyme-linked immunosorbent assay (ELISA) specific to antibodies against capsule biosynthesis protein CapA antigen of B. anthracis, which is non-cross-reactive to vaccine-induced antibodies in horses. Using in silico analyses, we screened coding sequences encoded on pXO2 plasmid, which is absent in the veterinary vaccine strain Sterne 34F2 but present in virulent strains of B. anthracis. Among the 8 selected antigen candidates, capsule biosynthesis protein CapA (GBAA_RS28240) and peptide ABC transporter substrate-binding protein (GBAA_RS28340) were detected by antibodies in infected horse sera. Of these, CapA has not yet been identified as immunoreactive in other studies to the best of our knowledge. Considering the protein solubility and specificity of B. anthracis, we prepared the C-terminus region of CapA, named CapA322, and developed CapA322-ELISA based on a horse model. Comparative analysis of the CapA322-ELISA and PAD1-ELISA (ELISA uses domain one of the PA) showed that CapA322-ELISA could detect anti-CapA antibodies in sera from infected horses but was non-reactive to sera from vaccinated horses. The CapA322-ELISA could contribute to the anthrax surveillance in endemic areas, and two immunoreactive proteins identified in this study could be additives to the improvement of current or future vaccine development.
format Online
Article
Text
id pubmed-8504768
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-85047682021-10-12 Development of ELISA based on Bacillus anthracis capsule biosynthesis protein CapA for naturally acquired antibodies against anthrax Zorigt, Tuvshinzaya Furuta, Yoshikazu Simbotwe, Manyando Ochi, Akihiro Tsujinouchi, Mai Shawa, Misheck Shimizu, Tomoko Isoda, Norikazu Enkhtuya, Jargalsaikhan Higashi, Hideaki PLoS One Research Article Anthrax is a zoonotic disease caused by the gram-positive spore-forming bacterium Bacillus anthracis. Detecting naturally acquired antibodies against anthrax sublethal exposure in animals is essential for anthrax surveillance and effective control measures. Serological assays based on protective antigen (PA) of B. anthracis are mainly used for anthrax surveillance and vaccine evaluation. Although the assay is reliable, it is challenging to distinguish the naturally acquired antibodies from vaccine-induced immunity in animals because PA is cross-reactive to both antibodies. Although additional data on the vaccination history of animals could bypass this problem, such data are not readily accessible in many cases. In this study, we established a new enzyme-linked immunosorbent assay (ELISA) specific to antibodies against capsule biosynthesis protein CapA antigen of B. anthracis, which is non-cross-reactive to vaccine-induced antibodies in horses. Using in silico analyses, we screened coding sequences encoded on pXO2 plasmid, which is absent in the veterinary vaccine strain Sterne 34F2 but present in virulent strains of B. anthracis. Among the 8 selected antigen candidates, capsule biosynthesis protein CapA (GBAA_RS28240) and peptide ABC transporter substrate-binding protein (GBAA_RS28340) were detected by antibodies in infected horse sera. Of these, CapA has not yet been identified as immunoreactive in other studies to the best of our knowledge. Considering the protein solubility and specificity of B. anthracis, we prepared the C-terminus region of CapA, named CapA322, and developed CapA322-ELISA based on a horse model. Comparative analysis of the CapA322-ELISA and PAD1-ELISA (ELISA uses domain one of the PA) showed that CapA322-ELISA could detect anti-CapA antibodies in sera from infected horses but was non-reactive to sera from vaccinated horses. The CapA322-ELISA could contribute to the anthrax surveillance in endemic areas, and two immunoreactive proteins identified in this study could be additives to the improvement of current or future vaccine development. Public Library of Science 2021-10-11 /pmc/articles/PMC8504768/ /pubmed/34634075 http://dx.doi.org/10.1371/journal.pone.0258317 Text en © 2021 Zorigt et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Zorigt, Tuvshinzaya
Furuta, Yoshikazu
Simbotwe, Manyando
Ochi, Akihiro
Tsujinouchi, Mai
Shawa, Misheck
Shimizu, Tomoko
Isoda, Norikazu
Enkhtuya, Jargalsaikhan
Higashi, Hideaki
Development of ELISA based on Bacillus anthracis capsule biosynthesis protein CapA for naturally acquired antibodies against anthrax
title Development of ELISA based on Bacillus anthracis capsule biosynthesis protein CapA for naturally acquired antibodies against anthrax
title_full Development of ELISA based on Bacillus anthracis capsule biosynthesis protein CapA for naturally acquired antibodies against anthrax
title_fullStr Development of ELISA based on Bacillus anthracis capsule biosynthesis protein CapA for naturally acquired antibodies against anthrax
title_full_unstemmed Development of ELISA based on Bacillus anthracis capsule biosynthesis protein CapA for naturally acquired antibodies against anthrax
title_short Development of ELISA based on Bacillus anthracis capsule biosynthesis protein CapA for naturally acquired antibodies against anthrax
title_sort development of elisa based on bacillus anthracis capsule biosynthesis protein capa for naturally acquired antibodies against anthrax
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504768/
https://www.ncbi.nlm.nih.gov/pubmed/34634075
http://dx.doi.org/10.1371/journal.pone.0258317
work_keys_str_mv AT zorigttuvshinzaya developmentofelisabasedonbacillusanthraciscapsulebiosynthesisproteincapafornaturallyacquiredantibodiesagainstanthrax
AT furutayoshikazu developmentofelisabasedonbacillusanthraciscapsulebiosynthesisproteincapafornaturallyacquiredantibodiesagainstanthrax
AT simbotwemanyando developmentofelisabasedonbacillusanthraciscapsulebiosynthesisproteincapafornaturallyacquiredantibodiesagainstanthrax
AT ochiakihiro developmentofelisabasedonbacillusanthraciscapsulebiosynthesisproteincapafornaturallyacquiredantibodiesagainstanthrax
AT tsujinouchimai developmentofelisabasedonbacillusanthraciscapsulebiosynthesisproteincapafornaturallyacquiredantibodiesagainstanthrax
AT shawamisheck developmentofelisabasedonbacillusanthraciscapsulebiosynthesisproteincapafornaturallyacquiredantibodiesagainstanthrax
AT shimizutomoko developmentofelisabasedonbacillusanthraciscapsulebiosynthesisproteincapafornaturallyacquiredantibodiesagainstanthrax
AT isodanorikazu developmentofelisabasedonbacillusanthraciscapsulebiosynthesisproteincapafornaturallyacquiredantibodiesagainstanthrax
AT enkhtuyajargalsaikhan developmentofelisabasedonbacillusanthraciscapsulebiosynthesisproteincapafornaturallyacquiredantibodiesagainstanthrax
AT higashihideaki developmentofelisabasedonbacillusanthraciscapsulebiosynthesisproteincapafornaturallyacquiredantibodiesagainstanthrax